Stereotactic Biopsy Split-Course Radiation Therapy in Diffuse Midline Glioma, SPORT-DMG Study
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age1+
SponsorMayo Clinic
About this trial
This phase II trial studies the clinical outcomes of hypofractionated radiation therapy in patients with diffuse midline gliomas. This study aims to change the way radiation is delivered, from giving 6 weeks of radiation all at once to giving 2 weeks of radiation. This may determine if there is a difference in the outcome of the treatment, and most importantly, the patients' quality of life.
Eligibility criteria
Qualifiers
Age >= 1 year(s) old (no maximum age)
Radiologic appearance of diffuse midline glioma of the pons, including diffuse infiltration of >= 50% of the pons on MRI, with or without extension to the midbrain and/or medulla oblongata with at least 1 of the 3 brainstem symptoms (cranial nerve deficit, long tract sign, or cerebellar sign)
If all features of this clinicoradiologic criteria are met, then patients can continue on protocol with or without a biopsy
If all features of this clinicoradiologic criteria are not met, patients must receive a brainstem lesion biopsy to be treated on protocol. If this cannot be completed, patients will be withdrawn from the study
Disqualifiers
Any patient who has received previous radiation to the brain
Any patient who has received previous chemotherapy
Any patient with a diagnosis of neurofibromatosis type 1 or 2 (NF1 or NF2)
Pregnant women
Trial design
Treatments tested in this trial
- Hypofractionated Radiation Therapy
- Questionnaire Administration
- Magnetic Resonance Imaging
- Positron Emission Tomography and Computed Tomography Scan
Treatment groups
29 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov